Company intelligence / Profile preview
Evive Biotech
Singapore, Singaporeevivebiotech.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Evive Biotech has successfully developed Ryzneuta®, which has been approved by the FDA, European Commission (EC), and China's NMPA[5].
- Therapeutic areas
- OncologyImmunologyMetabolic Disorders
- Modalities
- Biological therapies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Acrotech Biopharma (for F-627 commercialization in the US)Sino BiopharmaceuticalYifan PharmaceuticalIntegral Partners[3][5]
Beyond the preview
Go deeper on Evive Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evive Biotech.